From SA..."Vascepa will likely be approved in China by the end of 2021, based on several clinical studies confirming the efficacy and safety of this medicine."...
What's up with the delay?...Is price holding up the approval of Vascepa in China?...With over 100 million people in China able to profit from taking Vascepa...i.e. by having a reduction in CVD, Amarin can afford to negotiate a lower price for China.
Market Data 
Markets 
AI
